Concepts (252)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cost-Benefit Analysis | 30 | 2025 | 176 | 5.740 |
Why?
|
| Breast Neoplasms | 21 | 2024 | 1679 | 4.250 |
Why?
|
| Patient Readmission | 6 | 2023 | 120 | 3.710 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2020 | 209 | 2.870 |
Why?
|
| Budgets | 4 | 2025 | 15 | 2.460 |
Why?
|
| Decision Making | 9 | 2021 | 242 | 2.370 |
Why?
|
| Models, Economic | 11 | 2025 | 30 | 2.310 |
Why?
|
| Receptor, erbB-2 | 10 | 2020 | 149 | 2.010 |
Why?
|
| Drug Costs | 8 | 2025 | 36 | 1.950 |
Why?
|
| Decision Support Techniques | 8 | 2024 | 50 | 1.820 |
Why?
|
| Delayed-Action Preparations | 2 | 2025 | 72 | 1.760 |
Why?
|
| Antipsychotic Agents | 2 | 2025 | 81 | 1.720 |
Why?
|
| Delivery of Health Care | 8 | 2024 | 309 | 1.540 |
Why?
|
| Technology Assessment, Biomedical | 3 | 2024 | 9 | 1.470 |
Why?
|
| Humans | 70 | 2025 | 42163 | 1.450 |
Why?
|
| Myocardial Ischemia | 2 | 2023 | 82 | 1.420 |
Why?
|
| United States | 29 | 2025 | 5072 | 1.420 |
Why?
|
| Retrospective Studies | 17 | 2024 | 2485 | 1.240 |
Why?
|
| Medicare | 10 | 2025 | 326 | 1.210 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 116 | 1.210 |
Why?
|
| Hospital Mortality | 2 | 2020 | 206 | 1.190 |
Why?
|
| Female | 38 | 2025 | 24018 | 1.150 |
Why?
|
| Medication Adherence | 3 | 2025 | 177 | 1.010 |
Why?
|
| Alzheimer Disease | 2 | 2025 | 972 | 1.010 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 979 | 0.990 |
Why?
|
| Hospitalization | 5 | 2024 | 482 | 0.980 |
Why?
|
| Bibliometrics | 2 | 2024 | 15 | 0.920 |
Why?
|
| Opioid-Related Disorders | 3 | 2024 | 188 | 0.870 |
Why?
|
| Mastectomy, Segmental | 3 | 2022 | 25 | 0.850 |
Why?
|
| Schizophrenia | 1 | 2025 | 91 | 0.850 |
Why?
|
| Bipolar Disorder | 1 | 2025 | 83 | 0.850 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 43 | 0.820 |
Why?
|
| Aged | 19 | 2025 | 7982 | 0.810 |
Why?
|
| Quality-Adjusted Life Years | 11 | 2022 | 76 | 0.810 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 415 | 0.740 |
Why?
|
| Coronary Artery Disease | 1 | 2023 | 164 | 0.740 |
Why?
|
| Critical Illness | 1 | 2022 | 46 | 0.730 |
Why?
|
| Hepatic Encephalopathy | 1 | 2021 | 9 | 0.720 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 43 | 0.700 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 18 | 0.690 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2020 | 77 | 0.690 |
Why?
|
| Azithromycin | 1 | 2020 | 6 | 0.690 |
Why?
|
| Risk Factors | 8 | 2024 | 3942 | 0.690 |
Why?
|
| Logistic Models | 4 | 2023 | 1001 | 0.670 |
Why?
|
| Adult | 17 | 2025 | 13458 | 0.670 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 42 | 0.670 |
Why?
|
| Frail Elderly | 1 | 2020 | 18 | 0.660 |
Why?
|
| Attitude to Death | 1 | 2020 | 23 | 0.660 |
Why?
|
| Antimalarials | 1 | 2020 | 63 | 0.650 |
Why?
|
| Markov Chains | 6 | 2020 | 42 | 0.650 |
Why?
|
| Length of Stay | 4 | 2023 | 231 | 0.640 |
Why?
|
| Databases, Factual | 4 | 2023 | 336 | 0.640 |
Why?
|
| Life Expectancy | 1 | 2020 | 69 | 0.630 |
Why?
|
| Immunotherapy | 1 | 2021 | 137 | 0.630 |
Why?
|
| Sirolimus | 3 | 2014 | 70 | 0.630 |
Why?
|
| Piperazines | 1 | 2020 | 117 | 0.620 |
Why?
|
| Pyridines | 1 | 2020 | 134 | 0.620 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 168 | 0.610 |
Why?
|
| Stroke | 2 | 2020 | 348 | 0.610 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 118 | 0.600 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 181 | 0.590 |
Why?
|
| Treatment Outcome | 7 | 2020 | 1586 | 0.570 |
Why?
|
| Quality of Life | 3 | 2019 | 599 | 0.570 |
Why?
|
| Longevity | 1 | 2020 | 171 | 0.570 |
Why?
|
| Incretins | 1 | 2018 | 2 | 0.570 |
Why?
|
| Brain Ischemia | 1 | 2020 | 196 | 0.560 |
Why?
|
| Medication Therapy Management | 1 | 2018 | 9 | 0.560 |
Why?
|
| Middle Aged | 13 | 2025 | 11819 | 0.560 |
Why?
|
| Androstadienes | 2 | 2014 | 19 | 0.550 |
Why?
|
| Community Pharmacy Services | 1 | 2018 | 24 | 0.550 |
Why?
|
| Health Care Costs | 4 | 2024 | 89 | 0.540 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 363 | 0.540 |
Why?
|
| Attitude to Health | 1 | 2020 | 336 | 0.540 |
Why?
|
| Genetic Testing | 1 | 2018 | 90 | 0.530 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 233 | 0.520 |
Why?
|
| Drug Administration Schedule | 3 | 2025 | 153 | 0.510 |
Why?
|
| Time Factors | 5 | 2021 | 1848 | 0.500 |
Why?
|
| Male | 15 | 2025 | 22779 | 0.480 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2025 | 4 | 0.470 |
Why?
|
| Blood Glucose | 1 | 2018 | 386 | 0.470 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 2803 | 0.470 |
Why?
|
| Child | 6 | 2024 | 3381 | 0.460 |
Why?
|
| Injections | 2 | 2025 | 40 | 0.460 |
Why?
|
| Hormones | 1 | 2015 | 56 | 0.460 |
Why?
|
| Peptides | 1 | 2018 | 357 | 0.450 |
Why?
|
| Thiocarbamates | 1 | 2014 | 5 | 0.440 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2011 | 18 | 0.440 |
Why?
|
| Cost of Illness | 2 | 2025 | 95 | 0.430 |
Why?
|
| Reimbursement Mechanisms | 1 | 2013 | 11 | 0.420 |
Why?
|
| Economics, Medical | 1 | 2013 | 3 | 0.420 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2024 | 16 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 744 | 0.390 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 3077 | 0.380 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 366 | 0.370 |
Why?
|
| Formularies as Topic | 1 | 2011 | 3 | 0.370 |
Why?
|
| Child, Preschool | 5 | 2024 | 1516 | 0.360 |
Why?
|
| Hepatitis C, Chronic | 2 | 2022 | 44 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 53 | 0.360 |
Why?
|
| Developing Countries | 1 | 2011 | 112 | 0.350 |
Why?
|
| Cote d'Ivoire | 3 | 2020 | 7 | 0.350 |
Why?
|
| Decision Trees | 3 | 2020 | 22 | 0.350 |
Why?
|
| Prescription Drugs | 1 | 2011 | 32 | 0.340 |
Why?
|
| Young Adult | 7 | 2024 | 4936 | 0.320 |
Why?
|
| Melanoma | 2 | 2021 | 109 | 0.310 |
Why?
|
| Risk Assessment | 3 | 2024 | 845 | 0.310 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 358 | 0.300 |
Why?
|
| Drug Therapy, Combination | 2 | 2020 | 233 | 0.300 |
Why?
|
| Physicians | 1 | 2011 | 180 | 0.290 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 222 | 0.290 |
Why?
|
| Choice Behavior | 2 | 2021 | 91 | 0.280 |
Why?
|
| Norpregnenes | 1 | 2007 | 2 | 0.280 |
Why?
|
| Hot Flashes | 1 | 2007 | 8 | 0.280 |
Why?
|
| Adolescent | 5 | 2024 | 5950 | 0.280 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 19 | 0.280 |
Why?
|
| Disease Progression | 4 | 2025 | 661 | 0.270 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2007 | 42 | 0.270 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2021 | 471 | 0.260 |
Why?
|
| Taxoids | 2 | 2017 | 50 | 0.240 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 150 | 0.240 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 36 | 0.240 |
Why?
|
| Proteinuria | 1 | 2025 | 55 | 0.230 |
Why?
|
| Cost Savings | 1 | 2025 | 18 | 0.230 |
Why?
|
| Health Resources | 2 | 2016 | 37 | 0.230 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2024 | 4 | 0.230 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 62 | 0.230 |
Why?
|
| Teratogens | 1 | 2024 | 8 | 0.230 |
Why?
|
| Probability | 2 | 2016 | 82 | 0.230 |
Why?
|
| Costs and Cost Analysis | 1 | 2024 | 61 | 0.220 |
Why?
|
| Hepacivirus | 2 | 2022 | 73 | 0.220 |
Why?
|
| Health Care Sector | 1 | 2024 | 10 | 0.220 |
Why?
|
| Postmenopause | 2 | 2019 | 139 | 0.220 |
Why?
|
| Endrin | 1 | 2024 | 2 | 0.210 |
Why?
|
| Aortic Aneurysm | 1 | 2023 | 4 | 0.210 |
Why?
|
| Canada | 3 | 2016 | 157 | 0.210 |
Why?
|
| Substance-Related Disorders | 2 | 2021 | 825 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2024 | 143 | 0.200 |
Why?
|
| Antiviral Agents | 2 | 2022 | 189 | 0.200 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 729 | 0.190 |
Why?
|
| Drug Users | 1 | 2022 | 51 | 0.190 |
Why?
|
| Florida | 2 | 2021 | 461 | 0.180 |
Why?
|
| Propensity Score | 2 | 2023 | 58 | 0.180 |
Why?
|
| Sex Factors | 1 | 2025 | 1008 | 0.180 |
Why?
|
| Diabetic Nephropathies | 1 | 2022 | 74 | 0.180 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2022 | 128 | 0.180 |
Why?
|
| Depressive Disorder, Major | 1 | 2023 | 128 | 0.180 |
Why?
|
| Refuse Disposal | 1 | 2021 | 17 | 0.180 |
Why?
|
| Hospital Costs | 1 | 2021 | 28 | 0.170 |
Why?
|
| Hepatitis C | 1 | 2022 | 138 | 0.170 |
Why?
|
| Torsades de Pointes | 1 | 2020 | 2 | 0.170 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2020 | 5 | 0.170 |
Why?
|
| Patient Preference | 1 | 2021 | 55 | 0.170 |
Why?
|
| Papillomaviridae | 1 | 2022 | 136 | 0.170 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 20 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 28 | 0.170 |
Why?
|
| Long QT Syndrome | 1 | 2020 | 15 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 6 | 0.170 |
Why?
|
| Radiotherapy | 1 | 2020 | 21 | 0.170 |
Why?
|
| Prospective Studies | 2 | 2022 | 1574 | 0.170 |
Why?
|
| Radiosurgery | 1 | 2020 | 56 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 438 | 0.160 |
Why?
|
| Drugs, Generic | 1 | 2020 | 6 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 25 | 0.160 |
Why?
|
| Taiwan | 1 | 2019 | 21 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 90 | 0.160 |
Why?
|
| Cohort Studies | 2 | 2023 | 1729 | 0.160 |
Why?
|
| Vaccination | 1 | 2022 | 332 | 0.160 |
Why?
|
| Electrocardiography | 1 | 2020 | 184 | 0.160 |
Why?
|
| Survival Rate | 1 | 2020 | 353 | 0.160 |
Why?
|
| Nitriles | 1 | 2019 | 78 | 0.150 |
Why?
|
| Quinolines | 1 | 2020 | 76 | 0.150 |
Why?
|
| Computer Simulation | 2 | 2020 | 404 | 0.150 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 129 | 0.150 |
Why?
|
| Anticoagulants | 1 | 2020 | 121 | 0.150 |
Why?
|
| Triazoles | 1 | 2019 | 100 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2021 | 164 | 0.150 |
Why?
|
| Monte Carlo Method | 2 | 2016 | 66 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 130 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 121 | 0.140 |
Why?
|
| Ticlopidine | 1 | 2018 | 17 | 0.140 |
Why?
|
| Maytansine | 1 | 2017 | 2 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2018 | 362 | 0.140 |
Why?
|
| Adenosine | 1 | 2018 | 62 | 0.140 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 37 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 23 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 17 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2016 | 49 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2016 | 24 | 0.130 |
Why?
|
| Homosexuality, Male | 1 | 2022 | 483 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 532 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 174 | 0.130 |
Why?
|
| Mexico | 1 | 2017 | 286 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2018 | 358 | 0.120 |
Why?
|
| Infant | 3 | 2024 | 1143 | 0.120 |
Why?
|
| Prevalence | 1 | 2020 | 1597 | 0.120 |
Why?
|
| Vinblastine | 1 | 2015 | 9 | 0.120 |
Why?
|
| Drug Therapy | 1 | 2015 | 17 | 0.120 |
Why?
|
| Hypnotics and Sedatives | 1 | 2015 | 27 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 479 | 0.110 |
Why?
|
| Accidental Falls | 1 | 2015 | 31 | 0.110 |
Why?
|
| Age Factors | 1 | 2018 | 1139 | 0.110 |
Why?
|
| Decision Making, Organizational | 1 | 2014 | 6 | 0.110 |
Why?
|
| Health Records, Personal | 1 | 2014 | 6 | 0.110 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2015 | 70 | 0.110 |
Why?
|
| Incidence | 3 | 2024 | 1054 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2014 | 46 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 90 | 0.110 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 708 | 0.100 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 177 | 0.100 |
Why?
|
| Models, Theoretical | 1 | 2013 | 230 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 249 | 0.090 |
Why?
|
| Health Priorities | 1 | 2011 | 25 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2024 | 256 | 0.090 |
Why?
|
| National Health Programs | 1 | 2011 | 19 | 0.090 |
Why?
|
| Algorithms | 1 | 2014 | 508 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 238 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2024 | 960 | 0.080 |
Why?
|
| Social Class | 1 | 2011 | 286 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2018 | 2111 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 680 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 11 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2007 | 12 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 144 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2024 | 30 | 0.060 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2024 | 8 | 0.060 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 60 | 0.050 |
Why?
|
| Prescriptions | 1 | 2024 | 20 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2023 | 8 | 0.050 |
Why?
|
| SEER Program | 1 | 2024 | 157 | 0.050 |
Why?
|
| Macrolides | 1 | 2023 | 14 | 0.050 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 61 | 0.050 |
Why?
|
| Survivors | 1 | 2024 | 152 | 0.050 |
Why?
|
| Uncertainty | 1 | 2022 | 32 | 0.050 |
Why?
|
| Glucosides | 1 | 2022 | 21 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 49 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2021 | 35 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 245 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 47 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2022 | 245 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 95 | 0.040 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 4 | 0.040 |
Why?
|
| Palliative Care | 1 | 2020 | 61 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1737 | 0.040 |
Why?
|
| Aspirin | 1 | 2020 | 88 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2019 | 180 | 0.040 |
Why?
|
| Research Design | 1 | 2019 | 370 | 0.030 |
Why?
|
| Hippocampus | 1 | 2020 | 591 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 17 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 711 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 49 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 837 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 74 | 0.030 |
Why?
|
| Insulin | 1 | 2016 | 255 | 0.030 |
Why?
|